Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus maintenance in metastatic sarcoma
NCT01010672Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2009
- Primary completion
- Sep 2011
- Modality
- Classical Binding Small Molecules
01
Overview
A Phase 2 trial of ridaforolimus in bone sarcoma, soft tissue sarcoma (STS), sponsored by Merck & Co.. Started Nov 2009; status: completed.
02
Drugs
ridaforolimus
03
Conditions
bone sarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01010672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01010672.